Investigating the role of the palmaris longus muscle in Dupuytren's disease
The Potential Relationship Between the Palmaris Longus Muscle Prevalence and Dupuytren Disease: a Comparative Study
This study is trying to see if having a specific muscle in your arm affects the chances of developing or getting worse Dupuytren's disease in people aged 50 and older.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 240 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Universitaire Ziekenhuizen KU Leuven Academic / other |
| Locations | 1 site (Leuven, Vlaams-Brabant) |
| Trial ID | NCT06281509 on ClinicalTrials.gov |
What this trial studies
This study aims to explore the association between the presence of the palmaris longus muscle and the development, recurrence, and progression of Dupuytren's disease (DD). Participants aged 50 and older with DD will be compared to a control group of age-matched individuals without the condition. Non-invasive tests, including ultrasound, will be used to determine the presence of the palmaris longus tendon in both hands. The findings may provide insights into the predisposition of individuals to DD based on anatomical variations.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 50 and older who have Dupuytren's disease.
Not a fit: Patients under 50 years of age or those with cognitive impairments or other hand function-affecting conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of Dupuytren's disease and potentially lead to improved prevention and treatment strategies.
How similar studies have performed: Previous studies have indicated a potential link between the palmaris longus tendon and Dupuytren's disease, suggesting that this investigation builds on existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The participant or his/her legally authorized representative voluntary signed the informed consent prior to the first assessment. * 50 years of age or higher. * Has Dupuytren disease (primary or recurrent). (Only applicable for participants of DD group) * Has no medical conditions affecting the function of the hand (musculoskeletal pathology, vascular or neurological conditions such as CRPS, rheumatoid arthritis and paralysis). (Only applicable for participants of control group) Exclusion Criteria: * Patients \< 50 years * Patients with cognitive impairments. * Patients showing signs of medical conditions affecting the function of the hand (musculoskeletal pathology, vascular or neurological conditions such as CRPS, rheumatoid arthritis and paralysis). (Only applicable for participants of control group)
Where this trial is running
Leuven, Vlaams-Brabant
- Universitaire Ziekenhuizen KU Leuven — Leuven, Vlaams-Brabant, Belgium (Recruiting)
Study contacts
- Principal investigator: Ilse Degreef, Prof. Dr. — Universitaire Ziekenhuizen KU Leuven
- Study coordinator: Ilse Degreef, Prof. Dr.
- Email: ilse.degreef@uzleuven.be
- Phone: +32 16 33 88 43
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.